Carbidopa/levodopa (WD-1603) vs foslevodopa/foscarbidopa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Carbidopa/levodopa (WD-1603)
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
Reported efficacy
To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)
Result source: NCT05036473
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Reported efficacy
Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)
Result source: NCT04380142
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Carbidopa/levodopa (WD-1603) | foslevodopa/foscarbidopa |
|---|---|---|
| OFF time, change | —Not reported | -2.8 vs -1.0vs LD/CDNCT04380142 |
| ON time without troublesome dyskinesia, change | —Not reported | 2.7 vs 1.0vs LD/CDNCT04380142 |
| UPDRS Part III, change | —Not reported | —Not posted · NCT04379050 |
| MDS-UPDRS Part II, change | —Not reported | -2.6 vs -1.1vs LD/CDNCT04380142 |
OFF time, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- foslevodopa/foscarbidopa
- -2.8 vs -1.0vs LD/CDNCT04380142
ON time without troublesome dyskinesia, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- foslevodopa/foscarbidopa
- 2.7 vs 1.0vs LD/CDNCT04380142
UPDRS Part III, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- foslevodopa/foscarbidopa
- —Not posted · NCT04379050
MDS-UPDRS Part II, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- foslevodopa/foscarbidopa
- -2.6 vs -1.1vs LD/CDNCT04380142
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · foslevodopa/foscarbidopa: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Carbidopa/levodopa (WD-1603) | foslevodopa/foscarbidopa |
|---|---|---|
| Dropout rate | — | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 42.5%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 35.9%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Discontinued due to AEs | — | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 22.1%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 17.6%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Serious AEs | — | 8.1% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results25.8%ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 27.4%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 24.4%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Most frequent reported AEs | — | infusion site erythema 27% infusion site pain 25.7% infusion site cellulitis 17.6% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more resultsinfusion site erythema 52% infusion site nodule 28.7% infusion site oedema 19.3% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 high dose infusion site erythema 55.8% infusion site nodule 30.1% infusion site oedema 24.8% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 low dose infusion site erythema 48.9% infusion site nodule 27.5% infusion site cellulitis 19.1% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Carbidopa/levodopa (WD-1603)
show 2 more results
foslevodopa/foscarbidopa
show 17 more results
show 17 more results
show 17 more results
show 29 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · foslevodopa/foscarbidopa's landscape